AMS Advanced Medical Solutions Group plc
Advanced Medical Solutions Group plc, together with its subsidiaries, develops, manufactures, and distributes products for the surgical, woundcare, and wound-closure markets in the United Kingdom, Germany, France, Europe, the United States, and internationally. It offers surgical products, such as tissue adhesives, sutures and clips, haemostats, biosurgical, internal fixation devices, infection control, and internal sealants. The company also provides collagens, bone substitutes, resorbable fixation systems, vascular temporary occlusion, dressings, silicone wound contact layers, surgical supplies, debridement, hydrogels, and laparoscopic instruments. It sells its products under the LIQUIFIX, Peters Surgical, Ifabond, INTEGUSEAL, LiquiBand, RESORBA, LiquiBandFix8, Seal-G, Vitalitec, and ActivHeal brand names. The company provides wound care dressings, including silver alginates, alginates, and foams through its ActivHeal brand, as well as under white label. Advanced Medical Solutions Group plc was founded in 1991 and is headquartered in Winsford, the United Kingdom.…
Industry Peers
Medical Instruments & SuppliesKey Statistics
About Advanced Medical Solutions Group (LON: AMS)
›
Advanced Medical Solutions Group (LON: AMS) is listed on the London Stock Exchange, where its shares trade in pence sterling (GBp). It belongs to the Medical Instruments & Supplies industry, part of the Healthcare sector, and reports about 1,800 employees.
The shares were at 283.00 GBp on 19 November 2026, up 31.3% over 52 weeks.
At a market capitalisation of 616.92M GBP, it trades at 141.5 times trailing earnings and 16.6 times forward earnings. The median trailing P/E of its 19 largest Medical Instruments & Supplies peers is 49.2, a premium of 187% for AMS.
Advanced Medical Solutions Group reports return on equity of 3.8%, an operating margin of 10.3% and revenue up 4.2% year over year.
Its debt exceeds its cash by 71.81M GBP, a debt-to-equity ratio of 0.32. Its Piotroski F-score is 8 out of 9, a strong reading of its financial health. 6 analysts cover the stock; their mean price target of 292.50 GBp is 3.4% above the current price.